中国医疗健康：2025 年业绩前瞻及 2026 年初步展望：2025 年业绩前瞻及 2026 年初步展望-China Healthcare-China Pharma – 2025 Earnings Preview & Initial 2026 Outlook

China Healthcare | Asia Pacific January 28, 2026 05:41 PM GMT M Idea China Pharma – 2025 Earnings Preview & Initial 2026 Outlook Hengrui remains our Top Pick – we expect its product sales growth to accelerate in 2026, new deal momentum to be sustained, and more milestones to kick in. Globalization will remain a key investment theme, in particular pipeline advances and option exercise by partners to unlock milestone flows. Key Takeaways Related report: Catalyst Preview - China Pharma. See inside for: With th ...